Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000079949 | SCV000111832 | uncertain significance | not provided | 2015-06-22 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000631893 | SCV000752996 | uncertain significance | Maple syrup urine disease | 2021-09-01 | criteria provided, single submitter | clinical testing | This sequence change replaces alanine with valine at codon 2 of the DBT protein (p.Ala2Val). The alanine residue is moderately conserved and there is a small physicochemical difference between alanine and valine. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals affected with DBT-related conditions. ClinVar contains an entry for this variant (Variation ID: 94007). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Centre for Inherited Metabolic Diseases, |
RCV000631893 | SCV001431776 | likely pathogenic | Maple syrup urine disease | 2020-06-02 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000631893 | SCV002033182 | uncertain significance | Maple syrup urine disease | 2021-11-07 | criteria provided, single submitter | clinical testing |